Abbott Laboratories (ABT) Short term Debt (2009 - 2026)

Abbott Laboratories' Short term Debt history runs 18 years deep, the most recent figure standing at $4.4 billion for Q1 2026.

• In Q1 2026, Short term Debt rose 771.34% year-over-year to $4.4 billion; the TTM figure through Mar 2026 stood at $4.4 billion (up 771.34% YoY), while the FY2025 annual figure was $3.0 billion, up 102.2% from the prior year.
• Short term Debt came in at $4.4 billion for Q1 2026 at Abbott Laboratories, up from $3.0 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $4.4 billion in Q1 2026 to a low of $4.0 million in Q1 2022.
• A 5-year average of $1.6 billion and a median of $1.5 billion in 2024 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt sank 97.99% in 2022 and surged 57025.0% in 2023, its largest moves.
• Abbott Laboratories' Short term Debt stood at $2.3 billion in 2022, then slumped by 52.02% to $1.1 billion in 2023, then jumped by 38.89% to $1.5 billion in 2024, then soared by 102.2% to $3.0 billion in 2025, then surged by 45.37% to $4.4 billion in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $4.4 billion, $3.0 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison